SAN FRANCISCO–(BUSINESS WIRE)–Advocacy, the first context-driven AI platform for litigation, today released Promptless, a major expansion of its matter-centric technology that delivers AI support to litigation teams proactively—without prompting—while also giving a new level of primacy to human judgment in an AI litigation platform. Built on Advocacy’s existing document review, drafting, and collaboration features, Promptless eliminates the need for litigators to start AI-assisted work with a
Month: September 2026
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tigo Energy, Inc. (“Tigo” or the “Company”) (NASDAQ: TYGO) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON TIGO ENERGY, INC. (TYGO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On August 4,
NEW YORK–(BUSINESS WIRE)–The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below (“Securities”) of SilverBox Corp IV (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. Symbol Description SBXD Class A ordinary shares, par value $0.0001 per share SBXDU Units, each consisting of one Class A ordinary share, $0.0001 p
COVINGTON, La., Sept. 25, 2026 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq: POOL) announced today that its Board of Directors (the Board) appointed Jean-Marc Germain to serve as a director upon recommendation of the Nominating and Corporate Governance Committee. Mr. Germain’s appointment will be effective September 30, 2026, and he will serve until the 2027 annual meeting of shareholders, at which time he will stand for election by Pool Corporation’s shareholders. Following Mr. Germain’s appointment, the Board will consist of nine directors.
Mr. Germain is the former Chief Executive Officer of Constellium SE, a global leader in aluminum products and solutions. He served as Chief Executive Officer from 2016 to 2025 and currently serves as Special Advisor to the company’s board of directors. Prior to joining Constellium, he served as President and Chief Executive Officer of Algeco Scotsman Global from 2012 to 2016 and held numerous leadership roles at several international companies, including Novelis, Inc., Alcan, Inc., Pechiney, GE Capital and Bain & Co. Since 2021, Mr. Germain has served as an independent director of GrafTech International Ltd, a NYSE-listed manufacturer of high-quality graphite electrode products. He received his Master of Science from École Polytechnique in Paris.
John E. Stokely, Executive Chair of the Board, commented, “Jean-Marc brings extensive leadership, operational and governance experience from leading global industrial businesses. His proven ability to drive performance, navigate complex organizations and create shareholder value, combined with his public company board experience, makes him a valuable addition to our Board. We look forward to working with Jean-Marc as we continue to execute our strategy and deliver long-term value for our shareholders.”
About Pool Corporation
Pool Corporation is the world’s largest wholesale distributor of swimming pool and related backyard products. POOLCORP operates approximately 455 sales centers in North America, Europe and Australia through which it distributes more than 200,000 products to roughly 125,000 wholesale customers. For more information about POOLCORP, please visit www.poolcorp.com.
Forward-Looking Statements
This news release includes “forward-looking” statements that involve risks and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Actual results may differ materially due to a variety of factors, including risks detailed in POOLCORP’s 2025 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports and filings filed with the Securities and Exchange Commission (SEC) as updated by POOLCORP’s subsequent filings with the SEC.
CONTACT:
Kristin S. Byars
Director, Investor Relations and Finance
985.801.5153
kristin.byars@poolcorp.com
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
• ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings.
• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on Wednesday, September 30 at 1 PM EDT. BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the presentations will be available in the investor section of the Company’s website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company’s lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular proof-of-concept data from QUELL-CV are anticipated in the second half of 2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated in the second half of 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAgeʼs additional preclinical programs, which leverage insights from the Companyʼs proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
- Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.
- Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit.
VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended June 30, 2026.
The restatement revises the valuation of certain warrants and options, reducing previously reported stock-based compensation expense and warrant liabilities, with corresponding adjustments to unrealized gains and losses on warrant derivatives. The adjustments are non-cash and are expected to reduce previously reported non-cash operating expense and accumulated deficit.
The adjustments have no impact on the Company’s cash and cash equivalents, cash runway, or business operations.
The Company expects to file restated audited financial statements and related management’s discussion and analysis for the year ended December 31, 2025, including restated 2024 comparative figures and an adjustment to January 1, 2024 opening balances. The Company also expects to file restated unaudited interim financial statements and related management’s discussion and analysis for the quarter ended June 30, 2026.
The Company expects to complete these filings as soon as feasible and remains on track to report its third quarter 2026 financial results.
About NervGen
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Statements regarding the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, and other future events or developments constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company’s plans to restate previously issued financial statements and the scope and anticipated effects of the restatement; the expected non-cash nature of the adjustments and their effects on previously reported liabilities and other financial statement amounts; the expectation that the adjustments will have no impact on the Company’s cash, cash equivalents and marketable investments, cash runway or business operations; the anticipated timing of completing and filing the restated financial statements and related amended disclosures; the timing of reporting the Company’s third-quarter 2026 financial results; and other factors described in the “Risk Factors” section of the Company’s most recently filed Annual Information Form and Annual Report on Form 40-F, its management’s discussion and analysis for the year ended December 31, 2025, and subsequent filings with Canadian securities regulators and the U.S. Securities and Exchange Commission. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the SEC’s website at www.sec.gov. Readers should not place undue reliance on forward-looking statements made in this news release. Unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Contacts
On365 Partners, Investor Relations
ir@nervgen.com
203.293.8091
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) will host a conference call on Wednesday, October 21, 2026 to discuss the Company’s results for the third quarter ended September 30, 2026.
The conference call will begin at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). Prior to the conference call, the Company will issue a press release announcing the results and the associated presentation slides will be uploaded to the investor relations section of the Weatherford website.
Listeners can participate in the conference call via a live webcast. Alternatively, the conference call can be accessed by registering in advance (which will provide a PIN for immediate access) or by dialing +1 877-328-5344 (within the U.S.) or +1 412-902-6762 (outside of the U.S.) and asking for the Weatherford conference call. Participants should log in or dial in approximately 10 minutes prior to the start of the call.
A telephonic replay of the conference call will be available until November 04, 2026, at 5:00 p.m. Eastern Time. To access the replay, please dial +1 855-669-9658 (within the U.S.) or +1 412-317-0088 (outside of the U.S.) and reference conference number 2939769.
About Weatherford
Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.
Contact:
Luke Lemoine
Weatherford Investor Relations
+1 713-836-7777
investor.relations@weatherford.com
RAHWAY, N.J.–(BUSINESS WIRE)–The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit
FAIRMONT, W.Va.–(BUSINESS WIRE)– #banking–DingoBlu Financial, Inc., a financial technology company developing a mobile-first platform for personal financial products, today announced a strategic partnership with MVB Bank, Inc. The partnership represents an important milestone as DingoBlu prepares to introduce its platform and suite of financial products.DingoBlu is a Visa fintech partner, and its debit card program will run on the Visa network through its bank partner, MVB Bank. Through the relationship
NEW YORK–(BUSINESS WIRE)–The New York Times Company’s Board of Directors today declared a regular quarterly dividend of $0.23 per share on the Company’s Class A and Class B common stock. The dividend is payable on October 22, 2026, to shareholders of record as of the close of business on October 7, 2026. The New York Times Company (NYSE: NYT) is a trusted source of quality, independent journalism whose mission is to seek the truth and help people understand the world. With more than 13 millio